Abstract
Multiple DNA sequence variants in the form of single-nucleotide polymorphisms (SNPs) have been found to be reproducibly associated with prostate cancer (PCa) risk. Absolute risk for PCa among men with various numbers of inherited risk alleles and family history of PCa was estimated in a population-based case-control study in Sweden (2,893 cases and 1,781 controls), and a nested case-control study from the Prostate, Lung, Colon and Ovarian (PLCO) Cancer Screening Trial in the U.S. (1,172 cases and 1,157 controls). Increased number of risk alleles and positive family history were independently associated with PCa risk. Considering men with 11 risk alleles (mode) and negative family history as having baseline risk, men who had >or=14 risk alleles and positive family history had an odds ratio (OR) of 4.92 [95% confidence interval (CI): 3.64-6.64] in the Swedish study. These associations were confirmed in the U.S. population. Once a man's SNP genotypes and family history are known, his absolute risk for PCa can be readily calculated and easily interpreted. For example, 55-year-old men with a family history and >or=14 risk alleles have a 52% and 41% risk of being diagnosed with PCa in the next 20 years in the Swedish and U.S. populations, respectively. In comparison, without knowledge of genotype and family history, these men had an average population absolute risk of 13%. This risk prediction model may be used to identify men at considerably elevated PCa risk who may be selected for chemoprevention.
MeSH Terms
Case-Control Studies
Family Health
Genetic Markers
Genotype
Humans
Male
Middle Aged
Polymorphism, Single Nucleotide
Prostatic Neoplasms/epidemiology,genetics,prevention & control
Risk Factors
Sweden/epidemiology
United States/epidemiology
Chemicals
Genetic Markers
Authors & Affiliations
15 authors, click to expand affiliations / ORCID
Xu Jianfeng
Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. jxu@wfubmc.edu
Sun Jielin
Kader A Karim
Lindström Sara
Wiklund Fredrik
Hsu Fang-Chi
Johansson Jan-Erik
Zheng S Lilly
Thomas Gilles
Hayes Richard B
Kraft Peter
Hunter David J
Chanock Stephen J
Isaacs William B
Grönberg Henrik
References (27)
27 references, click to expand
-
Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.
Nat Rev Cancer. 2007 Dec;7(12):937-48
PMID: 18034184
-
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12.
Nat Genet. 2008 Oct;40(10):1153-5
PMID: 18758462
-
Genome-based prediction of common diseases: advances and prospects.
Hum Mol Genet. 2008 Oct 15;17(R2):R166-73
PMID: 18852206
-
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.
Nat Genet. 2007 May;39(5):631-7
PMID: 17401366
-
Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
Prostate. 2009 Aug 1;69(11):1195-205
PMID: 19434657
-
Prostate cancer epidemiology.
Lancet. 2003 Mar 8;361(9360):859-64
PMID: 12642065
-
Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density.
J Natl Cancer Inst. 2006 Sep 6;98(17):1215-26
PMID: 16954474
-
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24.
Nat Genet. 2007 May;39(5):645-9
PMID: 17401363
-
Predictive testing for complex diseases using multiple genes: fact or fiction?
Genet Med. 2006 Jul;8(7):395-400
PMID: 16845271
-
Multiple newly identified loci associated with prostate cancer susceptibility.
Nat Genet. 2008 Mar;40(3):316-21
PMID: 18264097
-
Sequence variants at 22q13 are associated with prostate cancer risk.
Cancer Res. 2009 Jan 1;69(1):10-5
PMID: 19117981
-
Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer.
Am J Med. 2005 Aug;118(8):850-7
PMID: 16084177
-
A new multipoint method for genome-wide association studies by imputation of genotypes.
Nat Genet. 2007 Jul;39(7):906-13
PMID: 17572673
-
When can a risk factor be used as a worthwhile screening test?
BMJ. 1999 Dec 11;319(7224):1562-5
PMID: 10591726
-
Multiple loci identified in a genome-wide association study of prostate cancer.
Nat Genet. 2008 Mar;40(3):310-5
PMID: 18264096
-
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP.
J Natl Cancer Inst. 2007 Dec 19;99(24):1836-44
PMID: 18073375
-
Converting relative risks to absolute risks: a graphical approach.
Stat Med. 1989 Jun;8(6):641-51
PMID: 2749072
-
Cumulative association of five genetic variants with prostate cancer.
N Engl J Med. 2008 Feb 28;358(9):910-9
PMID: 18199855
-
Variation in KLK genes, prostate-specific antigen and risk of prostate cancer.
Nat Genet. 2008 Sep;40(9):1032-4; author reply 1035-6
PMID: 19165914
-
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.
Nat Genet. 2007 Aug;39(8):977-83
PMID: 17603485
-
Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker.
Am J Epidemiol. 2004 May 1;159(9):882-90
PMID: 15105181
-
Prediction of individual genetic risk of complex disease.
Curr Opin Genet Dev. 2008 Jun;18(3):257-63
PMID: 18682292
-
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer.
Nat Genet. 2008 Mar;40(3):281-3
PMID: 18264098
-
The influence of finasteride on the development of prostate cancer.
N Engl J Med. 2003 Jul 17;349(3):215-24
PMID: 12824459
-
Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations.
Prostate. 2008 Sep 1;68(12):1257-62
PMID: 18491292
-
Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.
Prostate. 2009 Mar 1;69(4):419-27
PMID: 19116992
-
A common variant associated with prostate cancer in European and African populations.
Nat Genet. 2006 Jun;38(6):652-8
PMID: 16682969